Homocysteine remethylation enzyme polymorphisms and increased risks for neural tube defects

Molecular Genetics and Metabolism

Volumn 78, Issue 3, 2003, Pages 216-221

  Zhu, Huiping ^a   Wicker, Ned J ^a   Shaw, Gary M ^b   Lammer, Edward J ^c   Hendricks, Kate ^d   Suarez, Lucina ^d   Canfield, Mark ^d   Finnell, Richard H ^a,e  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b California Birth Defects Monitoring Program   (United States)

^c CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^d TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

^e TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Folate; Homocysteine; MTR; MTRR; Neural tube defects

Indexed keywords

HOMOCYSTINE; METHIONINE SYNTHASE; METHIONINE SYNTHASE REDUCTASE; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE INTERACTION; GENE LOCUS; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INFANT; METHYLATION; NEURAL TUBE DEFECT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SPINA BIFIDA;

EID: 0037341890     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-7192(03)00008-8     Document Type: Article

References (30)

1. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of Medical Research Council Vitamin Study. Lancet 338 (1991) 131-137.
2. Czeizel A., Dudas I. Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation. N. Engl. J. Med. 327:1992;1832-1835.
3. Berry R.J., Li Z., Erickson J.D., Li S., Moore C.A., Wang H., Mulinare J., Zhao P., Wong L.Y., Gindler J., Hong S.X., Correa A. Prevention of neural tube defects with folic acid in China. N. Engl. J. Med. 341:1999;1485-1490.
4. Shaw G.M., Lammer E.J., Zhu H., Baker M.W., Neri E., Finnell R.H. Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida. Am. J. Med. Genet. 108:2002;1-6.
5. Barber R.C., Shaw G.M., Lammer E.J., Greer K.A., Biela T.A., Lacey S.W., Wasserman C.R., Finnell R.H. Lack of association between mutations in the folate receptor-α gene and spina bifida. Am. J. Med. Genet. 76:1998;310-317.
6. Barber R., Shalat S., Hendricks K., Joggerst B., Larsen R., Suarez L., Finnell R. Investigation of folate pathway gene polymorphisms and the incidence of neural tube defects in a Texas Hispanic population. Molec. Genet. Metab. 70:2000;45-52.
7. Steegers-Theunissen R.P., Boers G.H., Trijbels F.J., Eskes T.K. Neural tube defects and derangement of homocysteine metabolism. New Engl. J. Med. 324:1991;199-200.
8. Steegers-Theunissen R.P., Boers G.H., Trijbels F.J., Finkelstein J.D., Blom H.J., Thomas C.M., Borm G.F., Wouters M.G., Eskes T.K. Maternal hyperhomocysteinemia: a risk factor for neural-tube defects? Meta. Clin. Exp. 43:1994;1475-1480.
9. Mills J.L., McPartlin J.M., Kirke P.N., Lee Y.J., Conley M.R., Weir D.G., Scott J.M. Homocystine metabolism in pregnancies complicated by neural tube defects. Lancet. 345:1995;149-151.
10. van der Put N.M.J., Blom H.J. Neural tube defects and a distrurbed folate dependent homocysteine metabolism. Eur. J. Obstet. Gynecol. Reprod. Biol. 92:2000;57-61.
11. Heil S.G., Lievers K.J., Boers G.H., Verhoef P., den Heijer M., Trijbels F.J., Blom H.J. Hyperhomocysteinemia and vascular disease in humans. Mol. Genet. Metab. 71:2000;511-519.
12. Botto L.D., Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am. J. Epidemiol. 151:2000;862-877. Review.
13. Watkins D., Rosenblatt D.S. Genetic heterogeneity among patients with methlycobalamin deficiency: definition of two complementation groups, cbIE and cbIG. J. Clin. Invest. 81:1988;1690-1694.
14. Watkins D., Rosenblatt D.S. Functional methionine synthase deficiency (cbIE and cbIG): clinical and biochemical heterogeneity. Am. J. Med. Genet. 34:1989;427-434.
15. Gulati S., Chen Z., Brody L.C., Rosenblatt D.S., Banerjee R. Defects in human methionine synthase in cb/G patients. Hum. Molec. Genet. 12:1996;1859-1865.
16. Leclerc D., Campeau E., Goyette P., Adjalla C.E., Christensen B., Ross M., Eydoux P., Rosenblatt D.S., Rozen R., Gravel R.A. Human methionine synthase: cDNA cloning and identification of mutations in patients of cbIG complementation group of folate/cobalamin disorders. Hum. Molec. Genet. 12:1996;1867-1874.
17. Ma J., Stampfer M.J., Christensen B., Giovannucci E., Hunter D.J., Chen J., Willett W.C., Selhub J., Hennekens C.H., Gravel R., Rozen R. A polymorphism of the methionine synthase gene: association with plasma folate, vitamin B12, homocysteine, and colorectal cancer risk. Cancer Epidemiol. 8:1999;825-829.
18. Christensen B., Arbour L., Tran P., Leclerc D., Sabbaghian N., Platt R., Gilfix B.M., Rosenblatt D.S., Gravel R.A., Forbes P., Rozen R. Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am. J. Med. Genet. 84:1999;151-157.
19. Morrison K., Edwards Y.H., Lynch S.A., Burn J., Hol F., Mariman E. Methionine synthase and neural tube defects. J. Med. Genet. 34:1997;958-960.
20. Shaw G.M., Todoroff K., Finnell R.H., Lammer E.J., Leclerc D., Gravel R.A., Rozen R. Infant methionine synthase variants and risk for spina bifida. J. Med. Genet. 36:1999;86-87.
21. Chen J., Stampfer M.J., Ma J., Selhub J., Malinow M.R., Hennekens C.H., Hunter D.J. Influence of a methionine synthase (D919G) polymorphism on plasma homocysteine and folate levels and relation to risk of myocardial infarction. Atherosclerosis. 154:2001;667-672.
22. Leclerc D., Wilson A., Dumas R., Gafuik C., Song D., Watkins D., Heng H.H., Rommens J.M., Scherer S.W., Rosenblatt D.S., Gravel R.A. Cloning and mapping of a cDNA for methionine synthase reductase, a flovoprotein defective in patients with homocystinuria. Natl. Acad. Sci. USA. 95:1998;3059-3064.
23. Wilson A., Platt R., Wu Q., Leclerc D., Christensen B., Yang H., Gravel R.A., Rozen R. A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Molec. Genet. Metab. 67:1999;317-323.
24. O'Leary V.B., Parle-McDermott A., Molloy A.M., Kirke P.N., Johnson Z., Conley M., Scott J.M., Mills J.L. MTRR and MTHFR polymorphism: link to Down syndrome? Am. J. Med. Genet. 107:2002;151-155.
25. Hobbs C.A., Sherman S.L., Yi P., Hopkins S.E., Torfs C.P., Hine R.J., Pogribna M., Rozen R., James S.J. Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome. Am. J. Hum. Genet. 67:2000;623-630.
26. Gaughan D.J., Kluijtmans L.A., Barbaux S., McMaster D., Young I.S., Yarnell J.W., Evans A., Whitehead A.S. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis. 157:2001;451-456.
27. Hendricks K.A., Simpson J.S., Larsen R.D. Neural tube defects along the Texas-Mexico border, 1993-1995. Am. J. Epidemiol. 149:1999;1119-1127.
28. Lucock M., Daskalakis I., Briggs D., Yates Z., Levene M. Altered folate metabolism and disposition in mothers affected by a spina bifida pregnancy: influence of 677c. → t methylenetetrahydrofolate reductase and 2756a → g methionine synthase genotypes Mol. Genet. Metab. 70:2000;27-44.
29. Olteanu H., Banerjee R. Human methionine synthase reductase, a soluble P-450 reductase-like dual flavoprotein, is sufficient for NADPH-dependent methionine synthase activation. J. Biol. Chem. 276:2001;35558-35563.
30. Doolin M.T., Barbaux S., McDonnell M., Hoess K., Whitehead A.S., Mitchell L.E. Maternal genetic effects, exerted by genes involved in homocysteine remethylation, influence the risk of spina bifida. Am. J. Hum. Genet. 71:2002;1222-1226.